Evidence map›Paper›PMID 25373867›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2015

Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells.

Stefan Bohr, Suraj J Patel, Radovan Vasko, Keyue Shen, Arvin Iracheta-Vellve, Jungwoo Lee, Shyam Sundhar Bale, Nilay Chakraborty, Michael Brines, Anthony Cerami and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Stefan BohrCenter for Engineering in Medicine/Surgical Services, Massachusetts General Hospital, Harvard Medical School, and Shriners Hospitals for Children, 51 Blossom Street, 4th Floor, Boston, MA, 02114, USA.
Suraj J Patel
Radovan Vasko
Keyue Shen
Arvin Iracheta-Vellve
Jungwoo Lee
Shyam Sundhar Bale
Nilay Chakraborty
Michael Brines
Anthony Cerami
Francois Berthiaume
Martin L Yarmush
Harvard University · USShriners Hospitals for Children - Erie · USAraim Pharmaceuticals (United States) · USRutgers Sexual and Reproductive Health and Rights · NLRutgers, The State University of New Jersey · USUniversitätsmedizin Göttingen · DE

Funding

Bio-MicroElectroMechanical Systems Resource CenterP41EB002503 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI TONER, MEHMET · 2004 to 2018
$17.4M
Improved Dermal Scaffolds for Skin RegenerationR21AR056446 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI BERTHIAUME, FRANCOIS · 2009 to 2010
$427k
NIAMS NIH HHS R21 AR056446NIAMS NIH HHS R21AR056446NIBIB NIH HHS P41 EB002503NIBIB NIH HHS P41EB002503
6 · The paper itself

Abstract

Tissue-protective properties of erythropoietin (EPO) have let to the discovery of an alternative EPO signaling via an EPO-R/CD131 receptor complex which can now be specifically targeted through pharmaceutically designed short sequence peptides such as ARA290. However, little is still known about specific functions of alternative EPO signaling in defined cell populations. In this study, we investigated effects of signaling through EPO-R/CD131 complex on cellular stress responses and pro-inflammatory activation in different mesenchymal-derived phenotypes. We show that anti-apoptotic, anti-inflammatory effects of ARA290 and EPO coincide with the externalization of CD131 receptor component as an immediate response to cellular stress. In addition, alternative EPO signaling strongly modulated transcriptional, translational, or metabolic responses after stressor removal. Specifically, we saw that ARA290 was able to overcome a TNFα-mediated inhibition of transcription factor activation related to cell stress responses, most notably of serum response factor (SRF), heat shock transcription factor protein 1 (HSF1), and activator protein 1 (AP1). We conclude that alternative EPO signaling acts as a modulator of pro-inflammatory signaling pathways and likely plays a role in restoring tissue homeostasis. Key message: Erythropoietin (EPO) triggers an alternative pathway via heteroreceptor EPO/CD131. ARA290 peptide specifically binds EPO/CD131 but not the canonical EPO/EPO receptor. Oxidative stress and inflammation promote cell surface expression of CD131. ARA290 prevents tumor necrosis factor-mediated inhibition of stress-related genes. Alternative EPO signaling modulates inflammation and promotes tissue homeostasis.

Indexed as

Stress, PhysiologicalAnimalsApoptosisCell LineCell MembraneCluster AnalysisCytokine Receptor Common beta SubunitCytokinesErythropoietinGene ExpressionGene Expression ProfilingImmunophenotypingInflammation MediatorsMaleMesenchymal Stem CellsMiceCytokine Receptor Common beta SubunitCytokinesErythropoietinInflammation MediatorsMultiprotein ComplexesReceptors, ErythropoietinTranscription Factors

Identifiers

PMID25373867
PMCPMC4482224
OpenAlexW2120753440

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.